Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder where the main risk factor is age, since its incidence increases dramatically after the age of 60. It is the most common form of dementia, and is accompanied by memory loss and cognitive impairment. Although AD was discovered over a century ago, the only drugs approved by the US Food and Drug Administration for use in its treatment are four cholinesterase inhibitors and memantine. However, these drugs are not fully effective in the treatment of AD. Therefore, the incessant search for new methods of treating AD continues, with the hope of improving both the effectiveness of therapies and the quality of life for patients suffering with AD. Current evidence suggests that the antibiotic minocycline could be a potential therapeutic drug for use in the treatment of AD due to its anti-neuroinflammatory effects. Minocycline is a tetracycline derivative that combines an anti-inflammatory property that is capable of crossing the blood brain barrier with neuroprotective properties that work by limiting inflammation and oxidative stress. Several studies have established the presence of inflammatory markers in the brains of patients suffering with AD, including elevated levels of cytokines/chemokines and microgliosis in damaged regions. Cytokines have been associated with increased tau phosphorylation and decreased levels of synaptophysin, establishing their roles in the cytoskeletal and synaptic alterations that take place in AD. Therefore, pharmacological approaches that allow for the discovery and development of new anti-inflammatory agents such as minocycline will be welcomed in the continuing struggle against AD. Considering these facts, this review will discuss the anti-inflammatory mechanisms underlying the neuroprotective effects of minocycline as a novel therapeutic approach for the treatment of AD.
Keywords: Alzheimer's disease, AD treatment, cytokine, minocycline, neuroinflammation, microglial activation.
Current Alzheimer Research
Title:The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease
Volume: 13 Issue: 12
Author(s): J. Budni, M. L. Garcez, J. de Medeiros, E. Cassaro, T. Bellettini-Santos, F. Mina and J. Quevedo
Affiliation:
Keywords: Alzheimer's disease, AD treatment, cytokine, minocycline, neuroinflammation, microglial activation.
Abstract: Alzheimer's disease (AD) is a neurodegenerative disorder where the main risk factor is age, since its incidence increases dramatically after the age of 60. It is the most common form of dementia, and is accompanied by memory loss and cognitive impairment. Although AD was discovered over a century ago, the only drugs approved by the US Food and Drug Administration for use in its treatment are four cholinesterase inhibitors and memantine. However, these drugs are not fully effective in the treatment of AD. Therefore, the incessant search for new methods of treating AD continues, with the hope of improving both the effectiveness of therapies and the quality of life for patients suffering with AD. Current evidence suggests that the antibiotic minocycline could be a potential therapeutic drug for use in the treatment of AD due to its anti-neuroinflammatory effects. Minocycline is a tetracycline derivative that combines an anti-inflammatory property that is capable of crossing the blood brain barrier with neuroprotective properties that work by limiting inflammation and oxidative stress. Several studies have established the presence of inflammatory markers in the brains of patients suffering with AD, including elevated levels of cytokines/chemokines and microgliosis in damaged regions. Cytokines have been associated with increased tau phosphorylation and decreased levels of synaptophysin, establishing their roles in the cytoskeletal and synaptic alterations that take place in AD. Therefore, pharmacological approaches that allow for the discovery and development of new anti-inflammatory agents such as minocycline will be welcomed in the continuing struggle against AD. Considering these facts, this review will discuss the anti-inflammatory mechanisms underlying the neuroprotective effects of minocycline as a novel therapeutic approach for the treatment of AD.
Export Options
About this article
Cite this article as:
Budni J., Garcez L. M., Medeiros de J., Cassaro E., Bellettini-Santos T., Mina F. and Quevedo J., The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease, Current Alzheimer Research 2016; 13 (12) . https://dx.doi.org/10.2174/1567205013666160819124206
DOI https://dx.doi.org/10.2174/1567205013666160819124206 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis
Current Neuropharmacology Infectious Burden: A New Risk Factor and Treatment Target for Atherosclerosis
Infectious Disorders - Drug Targets Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic:Gamma-Secretase Inhibitors and Modulators as a Therapeutic Approach to Alzheimers disease (Guest Editor: Bruno P. Imbimbo)]
Current Topics in Medicinal Chemistry Lysosomal Modulatory Drugs for a Broad Strategy Against Protein Accumulation Disorders
Current Alzheimer Research Emerging Therapeutic Targets in Regenerative Medicine for the Treatment of Diabetes Mellitus: A Patent Literature Review
Recent Patents on Regenerative Medicine Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Allosteric Enhancers for A1 Adenosine Receptor
Mini-Reviews in Medicinal Chemistry Lafora Progressive Myoclonus Epilepsy: Recent Insights into Cell Degeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design The Effect of <i>Stachy sieboldii</i> MIQ. Supplementation on Modulating Gut Microflora and Cytokine Expression in Mice
Combinatorial Chemistry & High Throughput Screening Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Subject Index To Volume 3
Vascular Disease Prevention (Discontinued) Chronic Alcohol Abuse and HIV Disease Progression: Studies with the Non-Human Primate Model
Current HIV Research Translating Genetic Findings into Therapy in Parkinson Disease
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Hot Topic : Computational Prediction of Drug-Target Interactions in Medicinal Chemistry)
Current Topics in Medicinal Chemistry Effects of the KIBRA Single Nucleotide Polymorphism on Synaptic Plasticity and Memory: A Review of the Literature
Current Neuropharmacology Sense and Sensibility When Prescribing ‘Off-Label’ to Psychiatric Patients
Current Pharmaceutical Design Recent Advances in the Development of Hybrid Molecules/Designed Multiple Compounds with Antiamnesic Properties
Mini-Reviews in Medicinal Chemistry